CG Oncology Stock Soars 22.44% After Earnings — Adding $1.3 Billion In Market Value

The bladder-cancer drug developer expects its $984.5 million reserve to fund operations through 2029 as trial readouts approach.

Share
CG Oncology Stock Soars 22.44% After Earnings — Adding $1.3 Billion In Market Value

CG Oncology, which develops experimental bladder-cancer treatments, soared 22.44% to $79.34 in Friday trading, as of 11:32 AM ET, adding $1.3 billion in market value. The gain followed its third-quarter results, which put revenue at $1.6 million and net loss at $56.9 million.

A Rally Beyond Its 56% Gain

CGON shares entered Friday already up 56% for the year at Thursday's close, against an 8% advance for the S&P 500 over the same period.

In Friday trading, CGON was on pace for its biggest one-day gain since Jan. 9, when it rose 29.3%. The company's total market value reached $7.03 billion in Friday trading, as of 11:32 AM ET.

Trial Costs Widen The Loss

The quarterly loss compared with $43.8 million a year earlier. The company spent $39.2 million on research versus $27.9 million a year earlier.

CG Oncology expects its $984.5 million reserve to cover operations through 2029. That funding outlook extends beyond the trial results the company anticipates in November and December.

Cretostimogene Readouts Approach

Cretostimogene is designed to attack cancer cells and enlist the immune system against tumors. Delivered into the bladder, the experimental treatment is being tested in patients whose high-risk or intermediate-risk cancer has not reached the bladder's muscle wall.

The company is studying the drug alone and with other cancer medicines in mid-stage and late-stage trials. As of January 30, 2026, over 740 patients had received cretostimogene across clinical studies; third parties manufacture the candidate.

Arthur Kuan, CG Oncology's chairman, president and CEO, said in the company's statement: “We remain confident in cretostimogene’s potential to become a backbone therapy for patients”.

CG Oncology anticipates initial results from its late-stage bladder-cancer trial in November, with additional trial data in December.

Sources

More on CG Oncology

All CG Oncology (CGON) coverage →